Adaptimmune raises $106M for pipeline work; KaloBios chief says biotech is on track for Chagas drug filing
→ Matrix Capital Management has scooped up $42 million worth of Adaptimmune stock $ADAP, paying a slight premium for the block of shares. “We are delighted to welcome Matrix to our shareholder base through a purchase of 7 million ADSs, which raises a further $42 million to add to the $62 million raised in our public offering, which closed last week,” says CEO James Noble.
→ Australia’s Novogen $NVGN is dropping a preclinical therapy after concluding that it didn’t have much of a future. It’s now cutting its headcount by an unspecified number and focusing on its clinical efforts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.